<DOC>
	<DOC>NCT00604006</DOC>
	<brief_summary>Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.</brief_summary>
	<brief_title>SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1. Was recruited to SCREENHF 2. Has provided informed consent 1. Uncorrected hyperkalaemia 2. eGFR &lt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Prevention of heart failure in individuals at high risk</keyword>
</DOC>